Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Pioglitazone (Primary)
- Indications Peripheral arterial disorders; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms PAD Wyeth
- 16 Mar 2012 Actual end date (19 Dec 2008) added as reported by EudraCT.
- 17 Jul 2007 New trial record.